Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Shares Outstanding for 1 consecutive years, with $12000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Shares Outstanding changed N/A to $12000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $12000.0, a N/A change, with the full-year FY2023 number at $12000.0, changed N/A from a year prior.
  • Shares Outstanding was $12000.0 for Q4 2023 at Inhibikase Therapeutics, roughly flat from $12000.0 in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $12000.0 in Q3 2023 to a low of $12000.0 in Q3 2023.